The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
 
Mustafa Özgüroğlu
Consulting or Advisory Role - Astellas Pharma; Bayer; Regeneron
Speakers' Bureau - Regeneron
Travel, Accommodations, Expenses - Regeneron
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Bayer
 
Benjamin Philip Levy
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Loxo (Inst); Merck (Inst); Turning Point Therapeutics (Inst)
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); BMKK (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Jinming Yu
No Relationships to Disclose
 
Ellie Grainger
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Patrick Hoang Phuong
Employment - Arcus Biosciences
Stock and Other Ownership Interests - Arcus Biosciences
 
Daniel Peterson
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Michael David Newton
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)